» Articles » PMID: 21242790

Hypertonic Saline Versus Mannitol for the Treatment of Elevated Intracranial Pressure: a Meta-analysis of Randomized Clinical Trials

Overview
Journal Crit Care Med
Date 2011 Jan 19
PMID 21242790
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Randomized trials have suggested that hypertonic saline solutions may be superior to mannitol for the treatment of elevated intracranial pressure, but their impact on clinical practice has been limited, partly by their small size. We therefore combined their findings in a meta-analysis.

Data Sources: We searched for relevant studies in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, and ISI Web of Knowledge.

Study Selection: Randomized trials were included if they directly compared equiosmolar doses of hypertonic sodium solutions to mannitol for the treatment of elevated intracranial pressure in human subjects undergoing quantitative intracranial pressure measurement.

Data Extraction: Two investigators independently reviewed potentially eligible trials and extracted data using a preformed data collection sheet. Disagreements were resolved by consensus or by a third investigator if needed. We collected data on patient demographics, type of intracranial pathology, baseline intracranial pressure, osms per treatment dose, quantitative change in intracranial pressure, and prespecified adverse events. Our primary outcome was the proportion of successfully treated episodes of elevated intracranial pressure.

Data Synthesis: Five trials comprising 112 patients with 184 episodes of elevated intracranial pressure met our inclusion criteria. In random-effects models, the relative risk of intracranial pressure control was 1.16 (95% confidence interval, 1.00-1.33), and the difference in mean intracranial pressure reduction was 2.0 mm Hg (95% confidence interval, -1.6 to 5.7), with both favoring hypertonic saline over mannitol. A mild degree of heterogeneity was present among the included trials. There were no significant adverse events reported.

Conclusions: We found that hypertonic saline is more effective than mannitol for the treatment of elevated intracranial pressure. Our meta-analysis is limited by the small number and size of eligible trials, but our findings suggest that hypertonic saline may be superior to the current standard of care and argue for a large, multicenter, randomized trial to definitively establish the first-line medical therapy for intracranial hypertension.

Citing Articles

Efficacy and Renal Safety of Protocol-based 11.7% Hypertonic Saline Infusion Compared with 20% Mannitol in Patients with Elevated Intracranial Pressure: A Study Protocol for a Randomized Clinical Trial.

Lim S, Yi Y Electrolyte Blood Press. 2025; 22(2):33-39.

PMID: 39780852 PMC: 11704315. DOI: 10.5049/EBP.2024.22.2.33.


No Benefit of 3% Hypertonic Saline Following Experimental Intracerebral Hemorrhage.

Kung T, Kalisvaart A, Suerte A, Jickling G, van Landeghem F, Colbourne F Neurotox Res. 2024; 42(6):44.

PMID: 39422850 PMC: 11489293. DOI: 10.1007/s12640-024-00722-2.


Mannitol inhibits the proliferation of neural stem cell by a p38 mitogen-activated protein kinase-dependent signaling pathway.

Duan H, Zhou X, Hu Q, Liu M, Wang S, Zhang J Chin J Traumatol. 2023; 27(1):42-52.

PMID: 37953130 PMC: 10859289. DOI: 10.1016/j.cjtee.2023.10.004.


A systematic review and meta-analysis on the efficacy of glibenclamide in animal models of intracerebral hemorrhage.

Kung T, Wilkinson C, Liddle L, Colbourne F PLoS One. 2023; 18(9):e0292033.

PMID: 37756302 PMC: 10529582. DOI: 10.1371/journal.pone.0292033.


Anaesthetic management in a cat undergoing emergency craniotomy for meningioma excision.

Marchionne G, Alcoverro E, Spinillo S, Louro L JFMS Open Rep. 2023; 9(2):20551169231192287.

PMID: 37744284 PMC: 10517613. DOI: 10.1177/20551169231192287.